Browse by author
Lookup NU author(s): Dr Simon Tual-Chalot, Dr Nikolaos VlachogiannisORCiD, Professor Konstantinos StellosORCiD, Professor Kimon Stamatelopoulos
This is the authors' accepted manuscript of a review that has been published in its final definitive form by Georg Thieme Verlag, 2021.
For re-use rights please refer to the publisher's terms and conditions.
© 2020 Georg Thieme Verlag. All rights reserved. Background-Accumulating evidence suggests that circulating amyloidβ 1-40 (Î'β1-40), a proatherogenic aging peptide, may serve as a novel biomarker in cardiovascular disease (CVD). We aimed to explore the role of plasma Î'β1-40 and its patterns of change over time in atherosclerosis progression in postmenopausal women, a population with substantial unrecognized CVD risk beyond traditional risk factors (TRFs). Methods âIn this prospective study, Î'β1-40 was measured in plasma by enzyme-linked immunosorbent assay and atherosclerosis was assessed using carotid high-resolution ultrasonography at baseline and after a median follow-up of 28.2 months in 152 postmenopausal women without history or symptoms of CVD. Results âAt baseline, high Î'β1-40 was independently associated with higher carotid bulb intima-media thickness (cbIMT) and the sum of maximal wall thickness in all carotid sites (sumWT) (p < 0.05). Î'β1-40 levels increased over time and were associated with decreasing renal function (p < 0.05 for both). Women with a pattern of increasing or persistently high Î'β1-40 levels presented accelerated progression of cbIMT and maximum carotid wall thickness and sumWT (p < 0.05 for all) after adjustment for baseline Î'β1-40 levels, TRFs, and renal function. Conclusion âIn postmenopausal women, a pattern of increasing or persistently high Î'β1-40 was associated with the rate of progression of subclinical atherosclerosis irrespective of its baseline levels. These findings provide novel insights into a link between Î'β1-40 and atherosclerosis progression in menopause and warrant further research to clarify the clinical value of monitoring its circulating levels as an atherosclerosis biomarker in women without clinically overt CVD.
Author(s): Lambrinoudaki I, Delialis D, Georgiopoulos G, Tual-Chalot S, Vlachogiannis NI, Patras R, Aivalioti E, Armeni E, Augoulea A, Tsoltos N, Soureti A, Stellos K, Stamatelopoulos K
Publication type: Review
Publication status: Published
Journal: Thrombosis and Haemostasis
Year: 2021
Volume: 121
Issue: 05
Pages: 650-658
Print publication date: 01/05/2021
Online publication date: 17/11/2020
Acceptance date: 10/10/2020
ISSN (print): 0340-6245
ISSN (electronic): 2567-689X
Publisher: Georg Thieme Verlag
URL: https://doi.org/10.1055/s-0040-1721144
DOI: 10.1055/s-0040-1721144
PubMed id: 33202443
